Overview

A Study of Niclosamide in Patients With Resectable Colon Cancer

Status:
Terminated
Trial end date:
2017-12-12
Target enrollment:
Participant gender:
Summary
This study evaluates the safety of Niclosamide in patients with colon cancer that are undergoing primary resection of their tumor. This is a phase I study with three dosage levels to determine the maximum tolerated dose (MTD).
Phase:
Phase 1
Details
Lead Sponsor:
Michael Morse, MD
Treatments:
Niclosamide